State of Alaska Department of Revenue Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT

State of Alaska Department of Revenue increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,214 shares of the medical instruments supplier’s stock after acquiring an additional 877 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.05% of LeMaitre Vascular worth $1,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of LMAT. GAMMA Investing LLC lifted its holdings in LeMaitre Vascular by 7,486.5% in the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier’s stock worth $4,519,000 after buying an additional 53,154 shares during the period. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular in the 1st quarter worth about $36,000. Vest Financial LLC purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $1,470,000. Compass Planning Associates Inc boosted its holdings in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier’s stock worth $988,000 after acquiring an additional 5,623 shares in the last quarter. Finally, Wesbanco Bank Inc. purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at approximately $470,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $87.85 on Monday. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 42.65, a price-to-earnings-growth ratio of 2.26 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The stock has a 50 day moving average price of $91.66 and a 200-day moving average price of $86.29. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period last year, the company earned $0.52 earnings per share. LeMaitre Vascular’s revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular’s dividend payout ratio is presently 38.83%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Saturday, September 27th. Cantor Fitzgerald upped their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Barrington Research restated an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Tuesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.60.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director owned 17,976 shares of the company’s stock, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John A. Roush sold 6,561 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director directly owned 2,916 shares in the company, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 120,815 shares of company stock valued at $11,280,206. Company insiders own 9.50% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.